ESR1 Mutations in HR+/HER2– Breast Cancer: Optimizing Testing Strategies and Treatment Decisions in the Era of Targeted Therapy

Targeted Therapies in HR+/HER2– Breast Cancer: Evidence-Based Strategies and Emerging Frontiers

ESR1 Mutations in HR+/HER2– Breast Cancer: Optimizing Testing Strategies and Treatment Decisions in the Era of Targeted Therapy

December 18th 2025

On October 6, 2025, a panel of medical oncologists specializing in advanced breast cancer participated in a virtual workshop to examine the optimization of testing strategies and treatment decisions for ESR1-mutated HR+/HER2- metastatic breast cancer.

Trending on OncLive

ESR1 Mutations in HR+/HER2– Breast Cancer: Optimizing Testing Strategies and Treatment Decisions in the Era of Targeted Therapy

ESR1 Mutations in HR+/HER2– Breast Cancer: Optimizing Testing Strategies and Treatment Decisions in the Era of Targeted Therapy

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

Five Under 5: Top Oncology Videos for the Week of 1/25

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma